Maravai LifeSciences Holdings Inc. Class A Common Stock vs SailPoint Inc. Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while SailPoint Inc. Common Stock trades at $19.49 (market cap $11.06B). The key difference: SailPoint Inc. Common Stock is far larger — about 11.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and SailPoint Inc. Common Stock is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and SailPoint Inc. Common Stock for 0 Days on average.
| MRVI | SAIL | |
|---|---|---|
Market Cap | $972.90M | $11.06B |
Volume | 4,325,710 | 3,269,663 |
Sector | Health | Technology |
52-Week High | $9.00 | $22.85 |
52-Week Low | $2.83 | $10.49 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $1.08B | $10.76B |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →SailPoint, Inc. develops identity security software that helps enterprises manage and govern access to applications and data across users, machines, and AI agents. Its unified identity security platform combines automation and intelligence to control identity-related risk at scale for large organizations.
Read more on SAIL →